Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Robertson

Showing results (511-520 of 565) with videos related to

Pageof 57
Sort By:
Lancet (London, England)|November 18, 2008
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysisM Juliana McElrath, Stephen C De Rosa, Zoe Moodie, et al.
Journal of Viral Hepatitis|February 11, 2019
Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infectionEric Lawitz, Fred Poordad, Leah J Anderson, et al.
Prostate Cancer and Prostatic Diseases|March 29, 2017
Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus ProjectK J Tay, M J Scheltema, H U Ahmed, et al.
AIDS Research and Human Retroviruses|December 26, 2008
Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adultsClayton D Harro, Michael N Robertson, Michelle A Lally, et al.
The Lancet. HIV|October 2, 2015
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trialJürgen K Rockstroh, Mark Nelson, Christine Katlama, et al.
Journal of Medicinal Chemistry|January 3, 2024
Design, Synthesis, and Evaluation of New 1<i>H</i>-Benzo[<i>d</i>]imidazole Based PqsR Inhibitors as Adjuvant Therapy for <i>Pseudomonas aeruginosa</i> InfectionsFadi Soukarieh, Alaa Mashabi, William Richardson, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 10, 2008
Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgeryWendy Demark-Wahnefried, Thomas J Polascik, Stephen L George, et al.
Gastroenterology|April 15, 2014
The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosisMichael P Manns, John M Vierling, Bruce R Bacon, et al.
AIDS Research and Human Retroviruses|September 22, 2010
Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy AdultsOuzama Nicholson, Fay DiCandilo, James Kublin, et al.
Hepatology (Baltimore, Md.)|February 24, 2018
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trialGraham R Foster, Kosh Agarwal, Matthew E Cramp, et al.
Pageof 57

Showing results (511-520 of 565) with videos related to

Sort By:
Pageof 57
Lancet (London, England)|November 18, 2008
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysisM Juliana McElrath, Stephen C De Rosa, Zoe Moodie, et al.
Journal of Viral Hepatitis|February 11, 2019
Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infectionEric Lawitz, Fred Poordad, Leah J Anderson, et al.
Prostate Cancer and Prostatic Diseases|March 29, 2017
Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus ProjectK J Tay, M J Scheltema, H U Ahmed, et al.
AIDS Research and Human Retroviruses|December 26, 2008
Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adultsClayton D Harro, Michael N Robertson, Michelle A Lally, et al.
The Lancet. HIV|October 2, 2015
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trialJürgen K Rockstroh, Mark Nelson, Christine Katlama, et al.
Journal of Medicinal Chemistry|January 3, 2024
Design, Synthesis, and Evaluation of New 1<i>H</i>-Benzo[<i>d</i>]imidazole Based PqsR Inhibitors as Adjuvant Therapy for <i>Pseudomonas aeruginosa</i> InfectionsFadi Soukarieh, Alaa Mashabi, William Richardson, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 10, 2008
Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgeryWendy Demark-Wahnefried, Thomas J Polascik, Stephen L George, et al.
Gastroenterology|April 15, 2014
The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosisMichael P Manns, John M Vierling, Bruce R Bacon, et al.
AIDS Research and Human Retroviruses|September 22, 2010
Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy AdultsOuzama Nicholson, Fay DiCandilo, James Kublin, et al.
Hepatology (Baltimore, Md.)|February 24, 2018
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trialGraham R Foster, Kosh Agarwal, Matthew E Cramp, et al.
Pageof 57